Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 8/20 | 0.46 |
| ▸ | FPR1 | P21462 | 7/20 | 0.45 |
| ▸ | FPR2 | P25090 | 4/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458054 | 0.90 | EPHX2 (0.44) | SSTR4KDM1AMAOBEPHX2SSTR1 | |
| SCHEMBL14722720 | 0.90 | EPHX2 (0.44) | SSTR4KDM1AMAOBEPHX2SSTR1 | |
| SCHEMBL461792 | 0.87 | FPR1 (0.46) | SSTR4FPR1FPR2 | |
| SCHEMBL121024 | 0.87 | FPR1 (0.46) | SSTR4FPR1FPR2 | |
| SCHEMBL12891129 | 0.85 | FPR1 (0.46) | SSTR4FPR1FPR2KDM1A | |
| SCHEMBL13178100 | 0.85 | FPR1 (0.46) | SSTR4FPR1FPR2KDM1A | |
| SCHEMBL7826671 | 0.83 | KDM1A (0.57) | SSTR4FPR1FPR2KDM1AMAOB | |
| SCHEMBL1721363 | 0.83 | KDM1A (0.50) | SSTR4FPR1FPR2KDM1ASSTR1 | |
| SCHEMBL458426 | 0.81 | EPHX2 (0.40) | SSTR4FPR1FPR2KDM1AMAOB | |
| SCHEMBL19988381 | 0.78 | FPR1 (0.62) | FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | SSTR4 145/4885FPR1 717/4885FPR2 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.